Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

4.820 +0.120 (+2.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 134,197
Open 4.810
Bid (Size) 4.500 (2)
Ask (Size) 4.740 (12)
Prev. Close 4.700
Today's Range 4.520 - 4.940
52wk Range 3.685 - 8.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease
Via Get News
The Latest Analyst Ratings for Coya Therapeutics
 
Via Benzinga

Performance

YTD
+3.66%
+3.66%
1 Month
-8.19%
-8.19%
3 Month
+3.10%
+3.10%
6 Month
+5.47%
+5.47%
1 Year
+5.47%
+5.47%

More News

Read More
Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
Via Benzinga
Blood Biomarker, Brain Imaging Data Shows Coya Therapeutics' Alzheimer's Candidate Lowers Neuroinflammation
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Coya Therapeutics: Another Sucess
Via Talk Markets
Why Coya Therapeutics Shares Are Shooting Higher Today
Via Benzinga
Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer’s Disease (AD)
From Coya Therapeutics, Inc.
Via Business Wire
Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer’s Disease (AD)
From Coya Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023
From Coya Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Via Benzinga
Tesla, Manchester United, Ohmyhome, Target, Coya: Why These 5 Stocks Are Drawing Investor Attention Today
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics, Inc. to Present at the Sidoti Virtual Investor Conference on Thursday, May 11, 2023, at 2:30pm ET
From Coya Therapeutics, Inc.
Via Business Wire
Positive Financials Along With Promising Clinical Results – Coya Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
Via Benzinga
Coya Therapeutics: An Attractive Valuation And First Set Of Data
Via Talk Markets
Alzheimer’s Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments - Could Regulatory T-Cells (Tregs) Be The Answer?
Via ACCESSWIRE
Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer?
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.